Core Viewpoint - 华检医疗 has experienced a significant stock price surge, driven by its strategic move into the RWA (Real World Assets) sector and the establishment of a global Ethereum (ETH) reserve strategy [1][2][10]. Company Strategy - On August 8, 华检医疗 announced the launch of a "Global Enhanced Ethereum (ETH) Treasury" strategy and formed a global strategic partnership with HashKey Group [1][2]. - The company plans to invest up to 8.8 billion HKD in purchasing ETH as reserve assets, with an initial purchase of 1.5 billion HKD already completed [1][2]. - 华检医疗 aims to create a Web3 exchange ecosystem focused on medical innovation assets, named "ivd.xyz," and plans to issue a stablecoin called IVDD [3][4]. Financial Performance - Since the market rally began on July 14, 华检医疗's stock price has increased by over 360%, reaching a peak of 12.86 HKD per share [1][2]. - The company's market capitalization currently stands at 150 billion HKD [1][2]. - The first batch of ETH purchased amounted to 5,190 coins at an average price of 3,661 USD each, resulting in a total transaction value of approximately 1.4947 billion HKD [2]. Market Context - The RWA sector has gained significant traction recently, with a reported global RWA asset total of 25.5 billion USD by mid-2025, driven by tokenization of real assets [10]. - The RWA market is currently dominated by private credit (58.5%), U.S. Treasury bonds (29.6%), and commodities (6.4%) [10]. Company Background - 华检医疗 is primarily an IVD (in vitro diagnostics) product distributor, with its own brand of IVD products [6][7]. - The company has faced fluctuating net profits since its IPO in 2019, with a notable decline in net profit expected for the first half of 2025 [6][7]. - 华检医疗's revenue structure shows that distribution business accounts for over 90% of total revenue, with self-branded products contributing only a small fraction [7]. Regulatory Environment - 华检医疗 has initiated the process to apply for a stablecoin license with U.S. regulatory authorities [5]. - The RWA sector is also seeing regulatory developments, with a registration platform launched in Hong Kong to facilitate the tokenization of assets [12].
最高斥资8.8亿港元买以太坊 ，华检医疗月内飙涨360%